Comparative Pharmacology
Head-to-head clinical analysis: RIFAMATE versus RIFATER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIFAMATE versus RIFATER.
RIFAMATE vs RIFATER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rifamate is a combination of rifampin and isoniazid. Rifampin inhibits bacterial RNA polymerase, blocking transcription. Isoniazid inhibits mycolic acid synthesis in the mycobacterial cell wall.
Rifater is a fixed-dose combination of rifampin, isoniazid, and pyrazinamide. Rifampin inhibits bacterial DNA-dependent RNA polymerase, blocking RNA synthesis. Isoniazid inhibits mycolic acid synthesis, disrupting bacterial cell wall. Pyrazinamide is converted to pyrazinoic acid, which disrupts membrane transport and energy metabolism.
2 capsules orally twice daily for 2 months followed by 1 capsule orally twice daily for 4 months. Each capsule contains rifampin 300 mg and isoniazid 150 mg.
RIFATER (rifampin/isoniazid/pyrazinamide) fixed-dose combination: 4 tablets (each tablet contains rifampin 120 mg, isoniazid 50 mg, pyrazinamide 300 mg) orally once daily for patients weighing ≥50 kg; for patients 40-49 kg, 3 tablets orally once daily; for 30-39 kg, 2 tablets orally once daily; for 20-29 kg, 1.5 tablets orally once daily. Administer on an empty stomach, 1 hour before or 2 hours after meals.
None Documented
None Documented
Rifampin: 3-4 hours (initial), 2-3 hours (after autoinduction); Isoniazid: 1-4 hours (fast acetylators), 0.5-1.5 hours (slow acetylators); Clinical context: Reduced in hepatic impairment; autoinduction decreases rifampin half-life after repeated dosing.
Rifampicin: 2-5 hours initially, prolonged to 5-7 hours after repeated dosing due to autoinduction. Isoniazid: 0.5-2 hours (fast acetylators), 2-5 hours (slow acetylators). Pyrazinamide: 9-10 hours.
Renal: 30% (rifampin unchanged), 15% (isoniazid unchanged); Biliary/Fecal: 60% (rifampin as metabolite), 5% (isoniazid); Additional: isoniazid metabolites (acetylisoniazid, isonicotinic acid) excreted renally.
Rifampicin: primarily hepatic (biliary) excretion, ~60% fecal, ~30% renal (unchanged and metabolites). Isoniazid: hepatic metabolism, renal excretion of metabolites (75-95% as isoniazid metabolites, <10% unchanged). Pyrazinamide: hepatic metabolism, renal excretion of metabolites (70% excreted in urine, 4-14% unchanged).
Category C
Category C
Antitubercular Combination
Antitubercular Combination